Literature DB >> 26490697

Helicobacter pylori treatment: Still a work in progress.

Frank J Senatore1, Jonathan Wilmot2, John W Birk2.   

Abstract

Helicobacter pylori is a common worldwide bacterium, possessing adaptability that has created difficulty achieving eradication. While the standard treatment was thought to be triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin, growing rates of treatment failure and antibiotic resistance have stimulated research into novel regimens. Quadruple therapy with bismuth has been compared for both first- and second-line treatments, but eradication still has not reached expected goals. Innovative regimens including sequential and concomitant therapy, as well as the introduction of new antibiotics into previous treatment schedules, have shown promising improvements in eradication rates. We discuss and compare these unique regimens, reviewing the current literature to deduce those which are most likely to provide the highest success in curing H. pylori infection.

Entities:  

Keywords:  Concomitant therapy; Helicobacter pylori eradication; Helicobacter pylori treatment; Quadruple therapy; Sequential therapy; Triple therapy

Mesh:

Substances:

Year:  2015        PMID: 26490697     DOI: 10.1080/00325481.2016.1103194

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  2 in total

Review 1.  Role of dupA in virulence of Helicobacter pylori.

Authors:  Amin Talebi Bezmin Abadi; Guillermo Perez-Perez
Journal:  World J Gastroenterol       Date:  2016-12-14       Impact factor: 5.742

2.  Detection of the clarithromycin resistance of Helicobacter pylori in gastric mucosa by the amplification refractory mutation system combined with quantitative real-time PCR.

Authors:  Xiao-Yan Zhang; Wei-Xiang Shen; Chun-Feng Chen; Hai-Hui Sheng; Hong Cheng; Jiang Li; Fulian Hu; Da-Ru Lu; Heng-Jun Gao
Journal:  Cancer Med       Date:  2019-03-12       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.